Navigation Links
Selexis SA to Present at Cell Line Development and Engineering 2013
Date:2/8/2013

Geneva, Switzerland (PRWEB) February 07, 2013

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the Company’s co-founder will present data on the Company’s core technology at the Cell Line Development and Engineering 2013 conference being held February 11 – 15 in Vienna, Austria. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression,” on Friday, February 15 at 1:45 PM as part of the CHO Cell Engineering tract.

Presentation Abstract
“Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression”
Incorporation of epigenetic regulatory DNA elements to prevent silencing can yield high and stable expression from CHO cells with a high frequency. We determined the sequence of a CHO genome used for pharmaceutical production and of derived therapeutic producing clones and allowed the characterisation of the alterations of the genomic and transgene sequence of candidate cell lines. This presentation will illustrate how a systematic and multi-level ‘Omics’ approach may be used to improve the expression of pharmaceutical proteins.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and morestable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/Cell_Line_Development/CHO_Cell/prweb10403820.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 19, 2017 , ... ... educational conference of the American Association of Bioanalysts (AAB) and the College of ... Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory services and ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science ... technologies ripe for commercialization, and who are affiliated with the 21 partner academic ... proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program ...
(Date:5/18/2017)... ... 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners II ... grow. CSM has doubled in size over the past six months with the ... , Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 ...
(Date:5/18/2017)... ... 2017 , ... Cognition Corporation ( http://www.cognition.us ), ... version 9.0 of the Cognition Cockpit platform. , “Our whole team has put ... CEO of Cognition. “We’re thrilled to finally be able to release it to ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):